RxDoctor Payments Data

Parvinderjit Khanuja, MD

Hematology & Oncology · Chandler, AZNPI 1053385765

Payments from drug & device makers

$11,895in general payments, 2019–2025

Across 383 payments — averaging $31.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mckesson Specialty Care Distribution, LLC$2K
  • US Oncology Corporate, Inc.$2K
  • Genentech USA, Inc.$656
  • Pfizer$637
  • Bristol Myers Squibb$554
  • AbbVie$552
  • plus $6K from 51 others

What the payments were for

  • Consulting fees$2,34520%
  • Travel & lodging$9818%
  • Food & beverage$8,29070%
  • Education$2592%
  • Gifts$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,895 in reported general payments places this provider in the 40th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$20,509
Medicare patients
66
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide12$167,588
Imatinib Mesylate15$1,122

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →